论文部分内容阅读
目的分析增液承气汤治疗小儿病毒性肺炎的临床疗效。方法 50例小儿病毒性肺炎患儿作为观察组,同期收治的50例小儿病毒性肺炎患儿设为对照组,予以对照组利巴韦林治疗,予以观察组增液承气汤治疗,比较两组的临床疗效。结果观察组总有效率为98%,对照组总有效率为78%,比较差异有统计学意义(P<0.05)。治疗后,观察组患儿的咳嗽消失时间为(5.62±2.18)d、退热时间为(2.42±1.68)d、喘促消失时间为(3.22±2.78)d、住院时间为(7.62±2.28)d、肺水泡音吸收时间为(5.14±2.08)d;对照组分别为(7.78±2.17)、(3.12±1.76)、(4.23±2.89)、(11.58±2.49)、(7.26±2.46)d;比较差异具有统计学意义(P<0.05)。观察组不良反应发生率为6%,对照组不良反应发生率为28%,比较差异有统计学意义(P<0.05)。结论增液承气汤治疗小儿病毒性肺炎,效果明显,安全性高,值得各级医院的推广应用。
Objective To analyze the clinical efficacy of Zhiku Chengqi Decoction in treating children with viral pneumonia. Methods 50 cases of children with viral pneumonia as observation group, 50 cases of children with viral pneumonia treated at the same period as a control group, to be the control group ribavirin treatment, to observe the treatment group, Group clinical efficacy. Results The total effective rate was 98% in observation group and 78% in control group, with significant difference (P <0.05). After treatment, the disappearance time of cough in observation group was (5.62 ± 2.18) d, (2.42 ± 1.68) d, (3.22 ± 2.78) d and (7.62 ± 2.28) days respectively) (5.18 ± 2.48) d and (4.14 ± 2.89), (11.58 ± 2.49) and (7.26 ± 2.46) d respectively in the control group, The difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 6%, and the incidence of adverse reactions in the control group was 28%, with statistical significance (P <0.05). Conclusion Increased fluid Chengqi Decoction in children with viral pneumonia, the effect is obvious, safe, it is worth the promotion and application of hospitals at all levels.